Zimmer Biomet Holdings Inc [ZBH] stock is trading at $90.79, up 0.29%. An important factor to consider is whether the stock is rising or falling in short-term value. The ZBH shares have gain 1.10% over the last week, with a monthly amount drifted -6.90%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Zimmer Biomet Holdings Inc [NYSE: ZBH] stock has seen the most recent analyst activity on December 16, 2025, when Robert W. Baird downgraded its rating to a Neutral but kept the price target unchanged to $100 for it. Previously, JP Morgan downgraded its rating to Neutral on November 06, 2025, and kept the price target unchanged to $100. On September 18, 2025, Rothschild & Co Redburn initiated with a Buy rating and assigned a price target of $130 on the stock. Roth Capital upgraded its rating to a Buy but stick to its price target of $135 on July 15, 2025. JP Morgan upgraded its rating to a Overweight and raised its price target to $128 on December 17, 2024. In a note dated July 01, 2024, Piper Sandler downgraded a Neutral rating on this stock and revised its target price from $140 to $115.
Zimmer Biomet Holdings Inc [ZBH] stock has fluctuated between $85.33 and $114.44 over the past year. Currently, Wall Street analysts expect the stock to reach $110.75 within the next 12 months. Zimmer Biomet Holdings Inc [NYSE: ZBH] shares were valued at $90.79 at the most recent close of the market. An investor can expect a potential return of 21.98% based on the average ZBH price forecast.
Analyzing the ZBH fundamentals
Zimmer Biomet Holdings Inc [NYSE:ZBH] reported sales of 8.01B for the trailing twelve months, which represents a growth of 9.71%. Gross Profit Margin for this corporation currently stands at 0.71% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.13%, and Net Profit Margin reading is 0.1%. To continue investigating profitability, this company’s Return on Assets is posted at 0.03, Equity is 0.06 and Total Capital is 0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.57.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 90.14 points at the first support level, and at 89.49 for the second support level. However, for the 1st resistance point, the stock is sitting at 91.18, and for the 2nd resistance point, it is at 91.57.
Ratios To Look Out For
For context, Zimmer Biomet Holdings Inc’s Current Ratio is 2.43. On the other hand, the Quick Ratio is 1.39, and the Cash Ratio is 0.72. Considering the valuation of this stock, the price to sales ratio is 2.25, the price to book ratio is 1.41 and price to earnings (TTM) ratio is 22.47.
Transactions by insiders
Recent insider trading involved Yi Sang, Group President, Asia Pacific, that happened on Sep 11 ’25 when 1200.0 shares were sold. Officer, Yi Sang completed a deal on Sep 11 ’25 to buy 1200.0 shares. Meanwhile, SVP and CHRO Winkler Lori sold 1500.0 shares on Sep 08 ’25.
